Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
J Clin Invest. 2011 Oct;121(10):3786-8. doi: 10.1172/JCI60534. Epub 2011 Oct 3.
Breast cancer is a heterogeneous disease. There is a high degree of diversity between and within tumors as well as among cancer-bearing individuals, and all of these factors together determine the risk of disease progression and therapeutic resistance. Advances in technologies such as whole-genome sequencing and functional viability screens now allow us to analyze tumors at unprecedented depths. However, translating this increasing knowledge into clinical practice remains a challenge in part due to tumor evolution driven by the diversity of cancer cell populations and their microenvironment. The articles in this Review series discuss recent advances in our understanding of breast tumor heterogeneity, therapies tailored based on this knowledge, and future ways of assessing and treating heterogeneous tumors.
乳腺癌是一种异质性疾病。肿瘤之间、肿瘤内部以及携带肿瘤的个体之间存在高度的多样性，所有这些因素共同决定了疾病进展和治疗耐药的风险。全基因组测序和功能活性筛选等技术的进步现在使我们能够以前所未有的深度分析肿瘤。然而，将这些不断增加的知识转化为临床实践仍然是一个挑战，部分原因是癌症细胞群体及其微环境的多样性驱动了肿瘤的进化。本综述系列中的文章讨论了我们对乳腺癌异质性的理解的最新进展、基于这些知识定制的治疗方法，以及评估和治疗异质性肿瘤的未来方法。
